sj-docx-1-tag-10.1177_17562848231155987 – Supplemental material for Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease

Supplemental material, sj-docx-1-tag-10.1177_17562848231155987 for Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease by Diogo Magalhaes, Laurent Peyrin-Biroulet, Maria Manuela Estevinho, Silvio Danese and Fernando Magro in Therapeutic Advances in Gastroenterology</p

Study selection flow chart.

<p>Study selection flow chart.</p

Composition of fecal microbiota in this model.

<p>(A) Composition of fecal microbiota (Family level) of control, arthritic, colitic or arthritic and colitic mice (N = 5) at days 14 (before induction of colitis), 21 (during colitis), 30 (after colitis) and 41 (after colitis). (B) Differential analysis between colitis and colitis + arthritis groups at day 21. (C) Differential analysis between arthritis and colitis + arthritis groups at day 21.</p

Analysis of joint inflammation and structural articular degradation in mice.

<p>Analyses were performed 41 days after arthritis sensitization and/or 27 days after colitis induction (N = 8 by group). (Aa) Macroscopic examination of ankle inflammation (Ab), histological grading of synovium infiltration and hyperplasia, cartilage degradation and bone erosion, (Ac) representative picture of ankles section (HES staining, X4 magnification) (Ad) representative sections of articular cartilage (toluidine blue staining, X10 magnification). (B) Measurement inflammatory cytokines and inflammation marker in forepaws (n = 5 by group) on day 41 by real time PCR. Data are expressed as mean ± SEM, # P<0.05 arthritis group <i>versus</i> control group, * P<0.05 arthritis + colitis group <i>versus</i> arthritis group.</p

Comparison of β-diversity between “arthritis + colitis” versus “arthritis” alone group.

<p>Anosim 9,999 permutations.</p

Colitis occurrence reduces arthritis severity.

<p>(A) Schematic representation of study design. Incidence of arthritis has been monitored (B) and clinical parameters, arthritis score (C) and hindpaws volume (D), have been measured in control, arthritic, colitic or arthritic and colitic mice (N = 8 by group). Arthritis was induced by injection of CII (200μg) at D0 at the basis of the tail and a boost of 100μg CII was performed at D21 by intra-peritoneal injection. Colitis was induced by oral intake of 3% DSS in drinking water from D14 to D21. Data are expressed as mean ± SEM. # P<0.05 arthritis group <i>versus</i> control group. * P<0.05 arthritis + colitis group <i>versus</i> arthritis group.</p

Diversity of fecal microbiota of control, arthritic, colitic or arthritic and colitic mice (N = 5) at days 14 (before induction of colitis), 21 (during colitis), 30 (after colitis) and 41 (after colitis).

<p>Arthritis was induced by injection of CII (200μg) at D0 at the basis of the tail and a boost of 100μg CII was performed at D21 by intraperitoneal injection. Colitis was induced by oral intake of 3% DSS in drinking water from D14 to D 21. (A) Representation of β-diversity of fecal microbiota. (B) Representation of α-diversity. Data are expressed as mean ± SEM. # P<0.05 colitis group <i>versus</i> control group. * P<0.05 arthritis + colitis group <i>versus</i> colitis group.</p

Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe

<p><b>Background</b>: This study aims to compare the cost-effectiveness of treatment sequences with available biologics, including adalimumab (ADA), biosimilar infliximab (bsIFX), originator infliximab (IFX) and vedolizumab (VEDO) for luminal Crohn’s disease in nine European countries.</p> <p><b>Methods</b>: A Markov-model was constructed to simulate five-year medical costs and quality-adjusted life years (QALYs). Data on clinical efficacy were obtained from randomised controlled trials. Country-specific unit costs, discount rates and a third-party payer perspective were applied.</p> <p><b>Results</b>: The bsIFX versus conventional therapy resulted in the most favourable incremental cost-utility ratios (ICURs) ranging from €34,580 (Hungary) to €77,062/QALY (Sweden). Compared to bsIFX, the bsIFX-ADA sequence was more cost-effective than the bsIFX-VEDO sequence with ICURs varying between €70,277 (France) and €162,069/QALY (Germany). The ICURs of the bsIFX-ADA-VEDO sequence versus the bsIFX-ADA strategy were between €206,266 (The Netherlands) and €363,232/QALY (Spain).</p> <p><b>Conclusion</b>: We are the first to compare cost-effectiveness of multiple biological sequences for luminal Crohn’s disease. Based on our findings, bsIFX can be recommended as a first-line treatment in patients unresponsive to conventional treatments. While biological sequences only slightly differ in their associated health gains, their costs vary greatly. The bsIFX-ADA-VEDO seems to be the most cost-effective sequence of the available biologics across Europe.</p

Plain language summary for the manuscript: Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme

This is a plain language summary (PLS) of an article published in a peer-reviewed scientific journal. This PLS is not peer-reviewed. The publisher of the original manuscript was not involved in the preparation of this PLS and has neither reviewed nor approved its content.</p